LF
LBRX

Longbow Finance’s LB Pharmaceuticals LBRX Stock Holding History

Longbow Finance’s Portfolio LBRX Stock Details LBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.67M Buy
+82,336
New +$2.42M 0.34% 58
2026
Q1 		– Sell
-82,336
Closed -$1.83M – 68
2025
Q4 		$1.83M Buy
+82,336
New +$1.44M 0.31% 60

Other funds holding LBRX

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Longbow Finance's LBRX Position: Q2 2026 in Review

Longbow Finance opened a new position in LB Pharmaceuticals (LBRX) in Q2 2026: 82,336 shares worth $2.67M. The stake represents 0.34% of the portfolio and ranks #58 among its holdings. This is a return to the name: Longbow Finance previously reported a position in LBRX as recently as Q4 2025.

Longbow Finance first reported a position in LBRX in Q4 2025 and has held it in 2 quarters since. 115 funds tracked by Wall St. Rank hold LBRX as of Q2 2026.

  • Longbow Finance held 82,336 shares of LB Pharmaceuticals worth $2.67M as of Q2 2026.
  • LB Pharmaceuticals was a new Longbow Finance position in Q2 2026.
  • LB Pharmaceuticals made up 0.34% of Longbow Finance's portfolio in Q2 2026, its #58 holding.
  • Longbow Finance first reported a position in LB Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 115 funds tracked by Wall St. Rank held LB Pharmaceuticals as of Q2 2026.

Based on Longbow Finance's 13F filing for Q2 2026, filed 29 Jul 2026.